Indomethacin suppository to prevent bladder catheter discomfort after prostate cancer surgery
Tests indomethacin suppositories against catheter bladder discomfort in men having laparoscopic prostate cancer surgery.
Plain-language title generated from the registry record
Registry title: Effects of Rectal Indomethacin Suppository on Postoperative CRBD in Patients Undergoing LRP
Key facts
- Where
- Hangzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07607990, who can take part
Where in China
- The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhejiang University
- Trial code
- NCT07607990
- Record updated
- 27 May 2026
- Original description
The postoperative incidence of catheter-related bladder discomfort (CRBD) ranges from 47% to 95%. It increases postoperative pain and agitation, thus requiring early intervention. Although a variety of drugs are used for the prevention or treatment of CRBD, the adverse reactions of most of these drugs have limited their clinical application. In long-term clinical practice, we found that indomethacin suppository has a good therapeutic effect on the discomfort of pelvic-related organs caused by nociceptive stimulation. However, its preventive effect on CRBD has not been reported yet. We hypothesized that indomethacin suppository has a preventive effect on postoperative CRBD. To verify this hypothesis, patients undergoing laparoscopic radical prostatectomy were enrolled in the study. Patients in the intervention group received 50 mg of indomethacin suppository via the rectal route immediately after surgery, while those in the control group received no treatment. The severity of CRBD, pain scores, consumption of analgesics, other perioperative adverse reactions, and patient satisfaction were observed and recorded at 0, 1, 2, and 6 hours after surgery.Read full original descriptionShow less
Effects of Rectal Indomethacin Suppository on Postoperative Catheter-Related Bladder Discomfort in Patients Undergoing Laparoscopic Radical Prostatectomy: A Randomized Controlled Trial
The postoperative incidence of catheter-related bladder discomfort (CRBD) ranges from 47% to 95%. It increases postoperative pain and agitation, thus requiring early intervention. Although a variety of drugs are used for the prevention or treatment of CRBD, the adverse reactions of most of these drugs have limited their clinical application. In long-term clinical practice, we found that indomethacin suppository has a good therapeutic effect on the discomfort of pelvic-related organs caused by nociceptive stimulation. However, its preventive effect on CRBD has not been reported yet. We hypothesized that indomethacin suppository has a preventive effect on postoperative CRBD. To verify this hypothesis, patients undergoing laparoscopic radical prostatectomy were enrolled in the study. Patients in the intervention group received 50 mg of indomethacin suppository via the rectal route immediately after surgery, while those in the control group received no treatment. The severity of CRBD, pain scores, consumption of analgesics, other perioperative adverse reactions, and patient satisfaction were observed and recorded at 0, 1, 2, and 6 hours after surgery.
Inclusion: Aged 18 to 80 years old (inclusive); American Society of Anesthesiologists (ASA) physical status classification Class I-III; Undergoing elective laparoscopic radical prostatectomy under general anesthesia; Having a clear understanding of the study, voluntarily participating, and providing informed consent signed by themselves or their family members.
Exclusion: Use of other nonsteroidal anti-inflammatory drugs (NSAIDs) within one week; Pre-existing bladder diseases, such as overactive bladder (frequency of micturition > 3 times per night or > 8 times within 24 hours), neurogenic bladder, and bladder outlet obstruction; Severe cardiac insufficiency (activity tolerance < 4 METs) or clearly diagnosed coronary heart disease; Clearly diagnosed chronic obstructive pulmonary disease (COPD) or a history of asthma; Hepatic insufficiency with Child-Pugh Class C; Chronic kidney disease requiring dialysis; Active peptic ulcer/hemorrhagic disease; Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs); Mental or neurological disorders that prevent the completion of rating scales; or cognitive impairment resulting in the loss of capacity for civil conduct; Postoperative status of pelvic organs or spine that affects bladder function; Postoperative status of total proctocolectomy; Body mass index (BMI) ≤ 18 kg/m² or ≥ 28 kg/m²; Chronic analgesic abuse.